Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Placebo-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of SAAVI DNA-C2 Vaccine Boosted by SAAVI MVA-C Vaccine, With or Without Novartis Sub C gp140 Vaccine With MF59 Adjuvant, in HIV Uninfected Healthy Vaccinia Naive Adult Participants in South Africa and the United States.

Next Previous
Trial Profile

A Phase 1 Placebo-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of SAAVI DNA-C2 Vaccine Boosted by SAAVI MVA-C Vaccine, With or Without Novartis Sub C gp140 Vaccine With MF59 Adjuvant, in HIV Uninfected Healthy Vaccinia Naive Adult Participants in South Africa and the United States.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HIV DNA vaccine; HIV gp140 vaccine; HIV vaccine; MF 59
  • Indications HIV-1 infections
  • Focus Adverse reactions

Most Recent Events

  • 02 Jun 2016 Biomarkers information updated
  • 17 Oct 2013 Status of the extension trial changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (Extension trial; NCT01423825).
  • 17 Oct 2013 Status of the extension trial changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (Extension trial; NCT01423825).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top